Latest Hematological malignancy Stories
Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912.
Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system.
In recent years, mutations in two metabolic enzymes, isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2), have been identified in approximately 20 percent of all acute myeloid leukemias (AML).
Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease.
Grant Program Addresses Three Critical Areas of Blood Cancer Research WHITE PLAINS, N.Y., Jan.
RARITAN, N.J., Jan.
WHITE PLAINS, N.Y., Jan.
SEATTLE, Jan. 2, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received notification from the U.S.
Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers.
The Leukemia & Lymphoma Society (LLS) is celebrating the successful culmination of this year's Light The Night Walk fund raising campaign. Los Angeles,
- Growing in low tufty patches.